$BCDA
BioCardia, Inc.

2024 Q4 Form 10-Q Financial Statement

#000143774924034896 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00 $357.0K
YoY Change -100.0% 68.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $825.0K $1.083M
YoY Change -23.82% -3.99%
% of Gross Profit
Research & Development $931.0K $1.872M
YoY Change -50.27% -12.69%
% of Gross Profit
Depreciation & Amortization $16.00K $21.00K
YoY Change -23.81% -27.59%
% of Gross Profit
Operating Expenses $1.756M $2.955M
YoY Change -40.58% -9.69%
Operating Profit -$1.756M -$2.598M
YoY Change -32.41% -15.1%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $19.00K $24.00K
YoY Change -20.83% 700.0%
Pretax Income -$1.737M -$2.570M
YoY Change -32.41% -15.93%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.737M -$2.574M
YoY Change -32.52% -15.8%
Net Earnings / Revenue -721.01%
Basic Earnings Per Share -$0.61 -$0.12
Diluted Earnings Per Share -$0.61 -$0.12
COMMON SHARES
Basic Shares Outstanding 4.584M 2.124M 21.62M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.930M $1.840M
YoY Change 167.93% -72.4%
Cash & Equivalents $4.900M $1.800M
Short-Term Investments
Other Short-Term Assets $116.0K $180.0K
YoY Change -35.56% -3.74%
Inventory
Prepaid Expenses
Receivables $10.00K $104.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $5.056M $2.116M
YoY Change 138.94% -70.42%
LONG-TERM ASSETS
Property, Plant & Equipment $47.00K $114.0K
YoY Change -58.77% -39.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $171.0K $171.0K
YoY Change 0.0% -0.58%
Total Long-Term Assets $1.211M $1.631M
YoY Change -25.75% -19.46%
TOTAL ASSETS
Total Short-Term Assets $5.056M $2.116M
Total Long-Term Assets $1.211M $1.631M
Total Assets $6.267M $3.747M
YoY Change 67.25% -59.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $569.0K $507.0K
YoY Change 12.23% -42.84%
Accrued Expenses $28.00K $36.00K
YoY Change -22.22% -68.7%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.840M $3.330M
YoY Change -14.71% -9.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $674.0K $1.080M
YoY Change -37.59% -22.75%
Total Long-Term Liabilities $674.0K $1.080M
YoY Change -37.59% -22.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.840M $3.330M
Total Long-Term Liabilities $674.0K $1.080M
Total Liabilities $3.514M $4.407M
YoY Change -20.26% -13.28%
SHAREHOLDERS EQUITY
Retained Earnings -$157.8M -$150.1M
YoY Change 5.13% 9.1%
Common Stock $5.000K $22.00K
YoY Change -77.27% 22.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.753M -$660.0K
YoY Change
Total Liabilities & Shareholders Equity $6.267M $3.747M
YoY Change 67.25% -59.18%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$1.737M -$2.574M
YoY Change -32.52% -15.8%
Depreciation, Depletion And Amortization $16.00K $21.00K
YoY Change -23.81% -27.59%
Cash From Operating Activities -$2.611M -$2.410M
YoY Change 8.34% 20.14%
INVESTING ACTIVITIES
Capital Expenditures $2.000K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.000K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.122M -60.00K
YoY Change -10303.33% -182.19%
NET CHANGE
Cash From Operating Activities -2.611M -2.410M
Cash From Investing Activities -2.000K 0.000
Cash From Financing Activities 6.122M -60.00K
Net Change In Cash 3.509M -2.470M
YoY Change -242.06% 26.86%
FREE CASH FLOW
Cash From Operating Activities -$2.611M -$2.410M
Capital Expenditures $2.000K $0.00
Free Cash Flow -$2.613M -$2.410M
YoY Change 8.42% 20.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38999
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
23-2753988
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.87
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2827492
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1441043
us-gaap Costs And Expenses
CostsAndExpenses
10024000 usd
dei Entity Address Address Line1
EntityAddressAddressLine1
320 Soquel Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunnyvale
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Registrant Name
EntityRegistrantName
BioCardia, Inc
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1646000 usd
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94085
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
226-0120
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6570000 usd
dei Trading Symbol
TradingSymbol
BCDA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4584285
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3454000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9560000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
61000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9499000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1382070
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000925741
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4930000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1103000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
34000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
63000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
116000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
295000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
5056000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1461000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
94000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
993000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1261000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
171000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
171000 usd
CY2024Q3 us-gaap Assets
Assets
6267000 usd
CY2023Q4 us-gaap Assets
Assets
2987000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
569000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
890000 usd
CY2024Q3 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1900000 usd
CY2023Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2385000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
371000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
333000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2840000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3608000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
674000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
982000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
3514000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4590000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4523876
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4523876
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1577769
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1577769
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
160573000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
150570000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-157825000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152175000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2753000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1603000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6267000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2987000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
357000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
58000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
464000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
931000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1872000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2972000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
825000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1083000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2766000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
1756000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
2955000 usd
us-gaap Costs And Expenses
CostsAndExpenses
5738000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1756000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2598000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5680000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
30000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1737000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2574000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5650000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.79
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2129258
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4892000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
278000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3501000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1900000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
317000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
177000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2471000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3424000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1635000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
251000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2574000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-660000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1603000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
43000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
832000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
204000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2267000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2275000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
184000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1961000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
926000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6274000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
177000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1737000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2753000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5650000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9499000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
268000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
242000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
565000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
846000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
4000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-34000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
11000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-87000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-86000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-179000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-123000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-165000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-24000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-485000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
598000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-341000 usd
bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-270000 usd
bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-233000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5453000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8123000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10513000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3042000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1228000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
435000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9285000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2607000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3827000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5528000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1103000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7363000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4930000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1835000 usd
us-gaap Stock Issued1
StockIssued1
40000 usd
us-gaap Stock Issued1
StockIssued1
20000 usd
bcda Proceeds From Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
ProceedsFromIssuanceOfRestrictedStockUnitsInLieuOfCashBonus
0 usd
bcda Proceeds From Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
ProceedsFromIssuanceOfRestrictedStockUnitsInLieuOfCashBonus
564000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-157800000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4900000 usd
us-gaap Use Of Estimates
UseOfEstimates
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>(c)</i></b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> </td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 63pt;"> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include clinical accruals, share-based compensation, right-of-use assets and related liabilities, incremental borrowing rate, the useful lives of property and equipment, allowances for doubtful accounts and sales returns, and assumptions used for revenue recognition.</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>(e)</i></b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p> </td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 63pt;"> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Our cash at times exceeds federally insured limits of $250,000 per customer. On September 30, 2024, approximately 99% of our cash and cash equivalents were held by one financial institution and total cash and cash equivalents were approximately $4.6 million in excess of FDIC insurance limits. We have not recognized any losses from credit risks on such accounts since inception.</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q3 bcda Cash Percentage Held In One Financial Institution
CashPercentageHeldInOneFinancialInstitution
0.99 pure
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4600000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
793000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
788000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
746000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
694000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
94000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
16000 usd
us-gaap Depreciation
Depreciation
52000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
21000 usd
us-gaap Depreciation
Depreciation
64000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
121000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
121000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
362000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
362000 usd
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
122000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
364000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
117000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
353000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M2D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1074 pure
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
121000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
499000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
514000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
44000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1178000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
133000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1045000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
75000 usd
CY2024Q3 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
736000 usd
CY2023Q4 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
661000 usd
CY2024Q3 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
597000 usd
CY2023Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
1017000 usd
CY2024Q3 bcda Grant Liability Current
GrantLiabilityCurrent
470000 usd
CY2023Q4 bcda Grant Liability Current
GrantLiabilityCurrent
471000 usd
CY2024Q3 bcda Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
69000 usd
CY2023Q4 bcda Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
90000 usd
CY2024Q3 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1900000 usd
CY2023Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2385000 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
141889
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
94.5
bcda Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
2467104
bcda Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
3.1
bcda Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
-141889
bcda Class Of Warrant Or Right Expired During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredDuringPeriodWeightedAverageExercisePrice
94.5
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2467104
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.1
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
177000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
251000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
565000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
846000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
165784
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.67
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3177
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
9317
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
63.09
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
153290
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
109830
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
63.83
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2620394
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
324582
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>(12)</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Contingencies </b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-align: justify;">We may be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management is not aware of any current legal or administrative proceedings that are likely to have an adverse effect on our business, financial position, results of operations, or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>

Files In Submission

Name View Source Status
bcda-20240930_cal.xml Edgar Link unprocessable
0001437749-24-034896-index-headers.html Edgar Link pending
0001437749-24-034896-index.html Edgar Link pending
0001437749-24-034896.txt Edgar Link pending
0001437749-24-034896-xbrl.zip Edgar Link pending
bcda-20240930.xsd Edgar Link pending
bcda20240930_10q.htm Edgar Link pending
ex_739988.htm Edgar Link pending
ex_739989.htm Edgar Link pending
ex_739990.htm Edgar Link pending
ex_739991.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
bcda-20240930_def.xml Edgar Link unprocessable
bcda-20240930_lab.xml Edgar Link unprocessable
bcda-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcda20240930_10q_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending